These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29480525)

  • 1. High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery.
    Craven GB; Affron DP; Allen CE; Matthies S; Greener JG; Morgan RML; Tate EW; Armstrong A; Mann DJ
    Angew Chem Int Ed Engl; 2018 May; 57(19):5257-5261. PubMed ID: 29480525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent docking of large libraries for the discovery of chemical probes.
    London N; Miller RM; Krishnan S; Uchida K; Irwin JJ; Eidam O; Gibold L; Cimermančič P; Bonnet R; Shoichet BK; Taunton J
    Nat Chem Biol; 2014 Dec; 10(12):1066-72. PubMed ID: 25344815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel approach to the discovery of small-molecule ligands of CDK2.
    Martin MP; Alam R; Betzi S; Ingles DJ; Zhu JY; Schönbrunn E
    Chembiochem; 2012 Sep; 13(14):2128-36. PubMed ID: 22893598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparameter Kinetic Analysis for Covalent Fragment Optimization by Using Quantitative Irreversible Tethering (qIT).
    Craven GB; Affron DP; Kösel T; Wong TLM; Jukes ZH; Liu CT; Morgan RML; Armstrong A; Mann DJ
    Chembiochem; 2020 Dec; 21(23):3417-3422. PubMed ID: 32659037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.
    Lu X; Smaill JB; Patterson AV; Ding K
    J Med Chem; 2022 Jan; 65(1):58-83. PubMed ID: 34962782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Irreversible Tethering (qIT) for Target-directed Covalent Fragment Screening.
    Craven GB; Armstrong A; Mann DJ
    Bio Protoc; 2020 Dec; 10(24):e3855. PubMed ID: 33659502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing an Allosteric Pocket of CDK2 with Small Molecules.
    Christodoulou MS; Caporuscio F; Restelli V; Carlino L; Cannazza G; Costanzi E; Citti C; Lo Presti L; Pisani P; Battistutta R; Broggini M; Passarella D; Rastelli G
    ChemMedChem; 2017 Jan; 12(1):33-41. PubMed ID: 27860401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Characterization of an Irreversible Inhibitor of CDK2.
    Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
    Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors.
    Konze KD; Bos PH; Dahlgren MK; Leswing K; Tubert-Brohman I; Bortolato A; Robbason B; Abel R; Bhat S
    J Chem Inf Model; 2019 Sep; 59(9):3782-3793. PubMed ID: 31404495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.
    Guilinger JP; Archna A; Augustin M; Bergmann A; Centrella PA; Clark MA; Cuozzo JW; Däther M; Guié MA; Habeshian S; Kiefersauer R; Krapp S; Lammens A; Lercher L; Liu J; Liu Y; Maskos K; Mrosek M; Pflügler K; Siegert M; Thomson HA; Tian X; Zhang Y; Konz Makino DL; Keefe AD
    Bioorg Med Chem; 2021 Jul; 42():116223. PubMed ID: 34091303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library.
    Miura C; Shindo N; Okamoto K; Kuwata K; Ojida A
    Chem Pharm Bull (Tokyo); 2020; 68(11):1074-1081. PubMed ID: 33132374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Covalent Kinase Inhibitor from a DNA-Encoded Small-Molecule Library × Protein Library Selection.
    Chan AI; McGregor LM; Jain T; Liu DR
    J Am Chem Soc; 2017 Aug; 139(30):10192-10195. PubMed ID: 28689404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteome-wide covalent ligand discovery in native biological systems.
    Backus KM; Correia BE; Lum KM; Forli S; Horning BD; González-Páez GE; Chatterjee S; Lanning BR; Teijaro JR; Olson AJ; Wolan DW; Cravatt BF
    Nature; 2016 Jun; 534(7608):570-4. PubMed ID: 27309814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Definitive Pharmacophore Modelling Study on CDK2 ATP Pocket Binders: Tracing the Path of New Virtual High-Throughput Screenings.
    Tutone M; Culletta G; Livecchi L; Almerico AM
    Curr Drug Discov Technol; 2020; 17(5):740-747. PubMed ID: 31250757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72.
    Pettinger J; Carter M; Jones K; Cheeseman MD
    J Med Chem; 2019 Dec; 62(24):11383-11398. PubMed ID: 31725295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual Screening Using Pharmacophore Models Retrieved from Molecular Dynamic Simulations.
    Polishchuk P; Kutlushina A; Bashirova D; Mokshyna O; Madzhidov T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.